Compare BridgeBio Pharma Inc (BBIO) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Tesla, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Tesla, Inc. trades at $333.16 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 78.9× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| BBIO | TSLA | |
|---|---|---|
Market Cap | $16.61B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $489.88 |
52-Week Low | $47.29 | $298.16 |
Enterprise Value | $18.16B | $1.28T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Tesla (TSLA) trades at $330.87, up 0.7% today, amid mixed signals: technicals are bearish with support at $327 and resistance at $333, while fundamentals show elevated valuation ratios (P/E 306.37) but recent earnings beats. Revenue dipped to $94.83B in 2025, with net margin at 3.67%, as the company pivots toward AI and robotics. News highlights regulatory approval for self-driving software in Europe (Reuters, 2026-04-10) and a 315% surge in German registrations (Zacks, 2026-04-10).
Outlook: Tesla's stock faces headwinds from high valuation and slowing auto growth, but opportunities exist in AI and energy expansion. Risks include intense EV competition and execution challenges. Analysts are divided, with a consensus price target of $393.87 (40.74% buy ratings), suggesting cautious optimism if innovation delivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
